|
Search
Collections
Benchmarks
Upload document
Organization
Blueprint Medicines Corporation, Cambridge, Massachusetts, USA
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 poster
Poster
BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer